Enterococcus faecalis Specific Neutra™ Antibody Products

Struggling with antibiotic resistance in nosocomial infections or delayed therapeutic development for Enterococcus faecalis? Creative Biolabs' E. faecalis specific Neutra™ antibody products leverage high-precision hybridoma screening and epitope-specific engineering to accelerate your antimicrobial research while ensuring robust, reproducible outcomes.

Introduction to E. faecalis

Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium ubiquitously found in the human gastrointestinal tract and a leading cause of hospital-acquired infections. Its resilience under harsh conditions—such as high salinity, extreme pH, and broad-spectrum antibiotics—makes it a formidable pathogen. E. faecalis is particularly notorious for its role in catheter-associated urinary tract infections (CAUTIs), bacteremia, and infective endocarditis, often complicating treatment due to multidrug resistance (MDR) traits.

• Structure

The structural robustness of E. faecalis arises from its thick peptidoglycan layer, teichoic acids, and surface adhesins like Esp and Ace, which facilitate host cell attachment and biofilm formation. The cell envelope also harbors lipoteichoic acids (LTAs) that modulate immune evasion. Crucially, its virulence factor CylA (cytolysin A) acts as a pore-forming toxin, lysing erythrocytes and immune cells, while gelatinase (GelE) degrades host tissues and biofilm matrices.

• Related Signaling Pathways

E. faecalis disrupts host signaling via NF-κB and MAPK pathways, amplifying pro-inflammatory cytokine release (e.g., IL-6, TNF-α) and tissue damage. The bacterium also subverts the host immune response by suppressing complement activation and phagocytic clearance, partly mediated by surface protein interactions with TLR2 and TLR4.

• Related Diseases

E. faecalis is a key etiological agent in persistent infections, including endocarditis, CAUTIs, and postoperative bacteremia. Its propensity to colonize medical devices (e.g., catheters, prosthetic valves) and form biofilms complicates eradication, while MDR strains—resistant to vancomycin, aminoglycosides, and β-lactams—pose severe therapeutic challenges.

Fig.1 Four Phases of Enterococcus faecalis biofilm formation.¹

Applications of E. faecalis Neutralizing Antibodies

• Therapeutic Development

Neutralizing antibodies against CylA and GelE show promise in reducing virulence during acute infections. By blocking cytolysin activity, they mitigate tissue damage and sepsis progression, while GelE inhibition enhances antibiotic penetration into biofilms for synergistic eradication.

• Preventive Strategies

Prophylactic administration of anti-Esp antibodies in high-risk populations (e.g., catheterized patients) prevents bacterial adhesion and biofilm formation, significantly lowering infection rates. This approach is particularly valuable in surgical and immunocompromised cohorts.

• Diagnostic Advancements

Antibody-based assays using anti-E. faecalis probes enable rapid identification of MDR strains in clinical samples. These tools support early intervention and antimicrobial stewardship by distinguishing virulent isolates from commensal enterococci.

Our Anti-E. faecalis Antibodies

Creative Biolabs' anti-E. faecalis antibodies are engineered to neutralize critical virulence determinants:

- Anti-CylA Antibodies: Block cytolysin-mediated hemolysis and immune cell lysis, reducing systemic toxicity.

- Anti-GelE Antibodies: Inhibit biofilm maturation and tissue degradation, curtailing bacterial persistence.

- Anti-Esp Antibodies: Prevent bacterial adhesion to host cells and abiotic surfaces, disrupting colonization.

Validated for specificity across immunoassays (ELISA, Western blot) and functional studies, these antibodies enable precise in vitro and in vivo targeting of E. faecalis pathogenesis.

Creative Biolabs provides E. faecalis specific Neutra™ antibody products that combine rigorous validation, epitope precision, and cross-application flexibility to address the challenges of antibiotic resistance and biofilm-associated infections. Contact our team today to discuss customized solutions for your research or therapeutic development needs.

REFERENCE

1. Yang, Shipeng, et al. "Strategies and mechanisms targeting Enterococcus faecalis biofilms associated with endodontic infections: a comprehensive review." Frontiers in Cellular and Infection Microbiology 14 (2024): 1433313. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcimb.2024.1433313